Company intelligence / Profile preview

NanoMosaic

Waltham, Massachusetts, United States

Ownership: Private
Employees: ~10
Development stage: Other

Overview

NanoMosaic's platform has demonstrated the ability to distinguish between empty and full viral capsids for gene therapy QC and enabled highly sensitive, multiplex biomarker detection (e.g., Tau PT217/PT181) for neurology applications, with publications receiving academic recognition. The technology is primarily in preclinical/validation stages for clinical applications.

Therapeutic areas: OtherNeurology
Modalities: DeviceBiologicAntibody-drug conjugate
Industry: Molecular Diagnostics

Beyond the preview

Go deeper on NanoMosaic.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on NanoMosaic.

Explore the full profile